위식도역류 질환에서 양성자 펌프 억제제의 장기처방

키워드

참고문헌 (52)

1. Vakil N, "The Montreal definition and classification of gastroesophageal reflux disease : a global evidence-based consensus", Am J Gastroenterol, 101, pp.1900~1920 (2006)
2. Kahrilas PJ, "American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease", Gastroenterology, 135, pp.1383~1391 (2008)
3. Fock KM, "Asia-Pacific consensus on the management of gastroesophageal reflux disease : update", J Gastroenterol Hepatol, 23, pp.8~22 (2008)
4. 정혜경, "위식도역류질환 임상진료지침 개정안 2012", 대한소화기학회지, 60(4), pp.195~218 (2012), 대한소화기학회
5. Yang YX, "Safety of proton pump inhibitor exposure", Gastroenterology, 139, pp.1115~1127 (2010)
6. 정수진, "위식도 역류질환의 초 치료 및 유지치료에 관한 온라인 설문조사: 전국 2, 3차 의료기관 소화기내과 전문의를 대상으로", 대한소화기학회지, 54(6), pp.364~370 (2009), 대한소화기학회
7. Sharma VK, "Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis", Aliment Pharmacol Ther, 15, pp.227~231 (2001)
8. Sjöstedt S, "Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis", Aliment Pharmacol Ther, 22, pp.183~191 (2005)
9. Labenz J, "A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis : the EXPO Study", Aliment Pharmacol Ther, 21, pp.739~746 (2005)
10. Bardhan KD, "Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease", Am J Gastroenterol, 98(3), pp.40~48 (2003)
11. Bardhan KD, "Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group", BMJ, 318, pp.502~507 (1999)
12. Fass R, "Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastrooesophageal reflux disease-a double-blind, placebo-controlled, randomized study", Aliment Pharmacol Ther, 31, pp.950~960 (2010)
13. Zacny J, "Systematic review : the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients", Aliment Pharmacol Ther, 21, pp.1299~1312 (2005)
14. Bytzer P, "Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease", Pharmacol Ther, 20, pp.181~188 (2004)
15. Scholten T, "On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD : the ORION Trial", Digestion, 72, pp.76~85 (2005)
16. Bour B, "Long-term treatment of gastro‐oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole : on-demand treatment compared with continuous treatment", Aliment Pharmacol Ther, 21, pp.805~812 (2005)
17. Vasiliadis KV, "Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system", Am J Gastroenterol, 105, pp.308~313 (2010)
18. Peters MJ, "Meta-analysis of randomized clinical trials comparing open and laparoscopic anti-reflux surgery", Am J Gastroenterol, 104, pp.1548~1561 (2009)
19. Lundell L, "Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis", Clin Gastroenterol Hepatol, 7, pp.1292~1298 (2009)
20. 이상권, "Laparoscopic Nissen Fundoplication in Korean Patients with Gastroesophageal Reflux Disease", Yonsei Medical Journal, 50(1), pp.89~94 (2009), 연세대학교의과대학
21. Campos GM, "Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication", J Gastrointest Surg, 3, pp.292~300 (1999)
22. Zhang Q, "Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B)agonist baclofen in patients with gastro-oesophageal reflux disease", Gut, 50, pp.19~24 (2002)
23. Boeckxstaens GE, "A novel reflux inhibitor lesogaberan(AZD3355)as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy : a randomised placebocontrolled trial", Gut, 60, pp.1182~1188 (2011)
24. Kaltenbach T, "Are lifestyle measures effective in patients with gastroesophageal reflux disease? an evidence-based approach", Arch Intern Med, 166, pp.965~971 (2006)
25. Jacobson BC, "Body-mass index and symptoms of gastroesophageal reflux in women", N Engl J Med, 354, pp.2340~2348 (2006)
26. Comay D, "The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease : a cost-effectiveness analysis", Can J Gastroenterol, 22, pp.552~558 (2008)
27. Testoni PA, "0)with EsophyX for gastroesophageal reflux disease : long-term results and findings affecting outcome", Surg Endosc, 26, pp.1425~1435 (2012)
28. Hershcovici T, "Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors", Curr Opin Gastroenterol, 26, pp.367~378 (2010)
29. Fass R, "Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial", Clin Gastroenterol Hepatol, 4, pp.50~56 (2006)
30. Sgouros SN, "Refractory heartburn to proton pump inhibitors: epidemiology, etiology and management", Digestion, 73, pp.218~227 (2006)
31. Hungin AP, "Factors influencing compliance in long-term proton pump inhibitor therapy in general practice", Br J Gen Pract, 49, pp.463~464 (1999)
32. Gunaratnam NT, "Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease", Aliment Pharmacol Ther, 23, pp.1473~1477 (2006)
33. Diener U, "Esophageal dysmotility and gastroesophageal reflux disease", J Gastrointest Surg, 5, pp.260~265 (2001)
34. Shay S, "Multichannel intraluminal impedance (MII) in the evaluation of patients with persistent GERD symptoms despite proton pump inhibitors (PPI): a multicenter study", Gastroenterology, 124(1), pp.537~ (2003)
35. Zerbib F, "Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors", Gut, 57, pp.156~160 (2008)
36. Fass R, "Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study", Aliment Pharmacol Ther, 14, pp.1595~1603 (2000)
37. Fass R, "Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study", Aliment Pharmacol Ther, 14, pp.1595~1603 (2000)
38. Fass R, "Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial", Clin Gastroenterol Hepatol, 4, pp.50~56 (2006)
39. Furuta T, "Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole", Clin Pharmacol Ther, 72, pp.453~460 (2002)
40. Sugimoto M, "Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype", Aliment Pharmacol Ther, 36, pp.627~634 (2012)
41. Sharma P, "Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation: results from two randomized controlled studies", Aliment Pharmacol Ther, 29, pp.731~741 (2009)
42. Yang YX, "Long-term proton pump inhibitor therapy and risk of hip fracture", JAMA, 296, pp.2947~2953 (2006)
43. Targownik LE, "Use of proton pump inhibitors and risk of osteoporosisrelated fractures", CMAJ, 179, pp.319~326 (2008)
44. Corley DA, "Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients", Gastroenterology, 139, pp.93~101 (2010)
45. Hansen KE, "Do proton pump inhibitors decrease calcium absorption?", J Bone Miner Res, 25, pp.2786~2795 (2010)
46. Wright MJ, "Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial", J Bone Miner Res, 25, pp.2205~2211 (2010)
47. Jo Y, "Effect of proton pump inhibitors on bone metabolism in old age", Gastroenterology, 142, pp.328~ (2012)
48. Valuck RJ, "A case-control study on adverse effects : H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults", J Clin Epidemiol, 57, pp.422~428 (2004)
49. Den Elzen WP, "Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals", Aliment Pharmacol Ther, 27, pp.491~497 (2008)
50. Hess MW, "Systematic review : hypomagnesaemia induced by proton pump inhibition", Aliment Pharmacol Ther, 36, pp.405~413 (2012)
51. Leonard J, "Systematic review of the risk of enteric infection in patients taking acid suppression", Am J Gastroenterol, 102, pp.2047~2056 (2007)
52. Tleyjeh IM, "Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis", PLoS One, 7, pp.50836~ (2012)

관련 논문AI추천